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i N T r o d U C T i o N
Preamble
In most developed countries, including the Netherlands, 
cardiovascular disease (CVD) is a leading cause of 
morbidity, mortality, and health care costs. Guidelines 
for CVD prevention should contain a comprehensive, 
evidence-based strategy towards both primary and 
secondary prevention. In addition, guidelines should be 
aimed at a broad spectrum of health care providers, both 
in primary care as well as in more specialised hospital 
settings.
Until recently, different national guidelines existed for the 
management of hypercholesterolaemia and hypertension 
in the Netherlands, whereas the emphasis has nowadays 
shifted to management of global CVD risk. In addition, 
separate guidelines existed for primary care and hospital 
care settings. 
In 2001, the Medical Council of the Dutch Institute 
for Healthcare Improvement CBO took the initiative to 
develop a national multidisciplinary guideline for global 
cardiovascular risk management. This paper provides a 
summary and short commentary on this guideline.
Aims and scope
The aim was to establish a guideline for optimal and 
cost-effective primary and secondary CVD prevention. The 
guideline is based on assessment of absolute CVD risk 
and replaces previous separate guidelines for hypertension 
and hypercholesterolaemia. In addition, the guideline 
integrates separate guidelines for general and hospital-based 
practice, and is intended for use by general practitioners, 
medical specialists and allied health professionals, such 
as dieticians, physiotherapists, nurse practitioners, and 
physician assistants.
The guideline addresses the most common forms of CVD: 
coronary artery disease, cerebrovascular disease, and 
peripheral arterial disease. It does not address screening 
for CVD in the general population, genetic disorders of 
lipid metabolism or excessive forms of dyslipidaemia, and 
management of hyperglycaemia in diabetes mellitus. 
Finally, the Working Group emphasises that the 
recommendations reflect ‘best practice’ for the average 
patient, not statutory regulations for all individual patients. 
In general, the guideline advocates individualised care 
and shared decision making. Non-adherence to the 
recommendations is not a basis for formal complaints or 
financial sanctions (such as non-reimbursement by health 
insurance companies). Health care workers are advised, 
however, to document their motivation for not adhering to 
the guideline recommendations.
Methods
A guideline development group was formed, involving all 
the relevant professional disciplines. All group members as 
well as the associations they represented are listed at the end 
of this paper. The guideline development group comprised 
general practitioners (5), internists (3), cardiologists (3), a 
vascular surgeon, a neurologist, epidemiologists (5), a health 
economist, and two methodologists from the CBO.
The group started by discussing the European Guidelines 
on Cardiovascular Disease Prevention in Clinical Practice 
(Third Joint Task Force),1 as well as the existing national 
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guidelines for hypertension and for hypercholesterolaemia. 
Additional literature searches were conducted for updating 
the literature. The recommendations in the European 
guideline were used for adaptation to the Dutch context. 
Data on absolute CVD risk were derived from original 
Dutch epidemiological studies. The guideline working 
group formulated recommendations based on informal 
consensus within the group. The first draft of the guideline 
was finished in June 2005. This draft was sent for external 
review to all relevant stakeholders. The final guideline was 
endorsed by all scientific associations represented in the 
guideline development group in June 2006 
G U i d E l i N E  s U M M A r Y
The guideline is summarised in figure 1. This figure as well 
as the full text version of the guideline can be downloaded 
at www.cbo.nl/product/richtlijnen/folder20021023121843/
rl_overzicht. The full text version includes an extensive 
figure 1. Flowchart Dutch guideline cardiovascular risk management 2006 
Identification of patients with elevated risk of CVD
Patients with cardiovascular disease (CVD) Smoking men ≥50 years Systolic blood pressure ((SBP ≥140 mmHg   
Patients with diabetes mellitus type 2 (DM2) Smoking women ≥55 years Total cholesterol (TC) ≥6.5 mmol/l
Medical history
Smoking behaviour
Father, mother or sibling with CVD <60 years
Nutrition, alcohol intake, physical activity
Physical examination




Total cholesterol (TC), 




SBP >180 mmHg 
or TC >8 mmol/l 
or TC/HFL-
ratio >8
Patient with CVD 
or DM2
CVD risk estimation 






Optimise body weight (BMI <25 kg/m2, 
waist circumference <80 cm in women or <94 cm in min)
Sufficient physical exercise (at least) 5d/w 30 min)
Healthy food 
Restricted use of saturated fats, trans fats and salt 1 to 2/w (fat) 
fish at least 200 g vegetables and 2 pieces of fruit every day
Moderate alcohol intake (no more than 3U/d for men or 2U/d for women)
Patients with CVD Patients with DM2 Fatal CVD risk >10% Additional risk factors*
Drug treatment
Acetylsalicyl acid
Blood pressure lowering drugs 
if SBP ≥140 mmHg
Statins if LDL >2.5 mmol/l
Drug treatment
Blood pressure lowering drugs 
if SBP ≥140 mmHg
Statins if LDL >2.5 mmol/l
Glucose lowering drugs
Drug treatment
Blood pressure lowering drugs 
if SBP ≥140 mmHg
Statins (simvastatin or pravastatin) 
if LDL >2.5 mmol/l
Follow-up
Individual plan, considering risk profile, (co)morbidity, and patient preferences
At least annually after regulation of risk factors
Therapy/follow-up
Consider lifestyle recommendations
No drug treatment unless young patient with seriously 
abnormal or clustering of risk factors
Consider individual follow-up plan
Yes





*Additional risk factors: father, mother, brother or sister with CVd <60 years; obesitas (bMi >30 kg/m2, waist circumference >88 cm in women 
or >102 cm in men); end organ damage, such as (micro)albuminuria, impaired renal function or left ventricular hypertrophy.
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technical background document containing the supporting 
evidence as well as a budget impact analysis.
The subsequent steps of the guideline are outlined below. 
identification of high-risk patients
All patients with a previous CVD diagnosis are considered 
as high-risk patients. The risk of most patients with type 
2 diabetes mellitus (DM2) is also elevated. In both patient 
categories, a full risk profile should be obtained. In individuals 
without previous CVD or DM2, signs or symptoms, a family 
history of premature CVD, visible overweight or a specific 
request from the patient may prompt inquiry into smoking 
behaviour or measurement of blood pressure or serum 
cholesterol levels. It is recommended to obtain a complete 
CVD risk profile if one of the following is present:
systolic blood pressure ≥140 mmHg• 
total cholesterol ≥6.5 mmol/l• 
smoking in men ≥50 years or women ≥55 years of age.• 
diagnostic procedures 
A complete risk profile should be obtained by collecting 
information on the risk factors listed in figure 1. Blood 
pressure should be measured twice on at least two 
separate days, adhering to specific instructions outlined 
in the guideline. In addition to the recommended blood 
tests in figure 1, patients with hypertension require 
measurement of serum creatinine and potassium level. 
Testing for microalbuminuria and obtaining a 12-lead 
electrocardiogram can be considered in individual cases.
Additional investigation for secondary hypertension is 
warranted in case of:
specific clinical signs (e.g. Cushing habitus);• 
strongly elevated systolic blood pressure (>180 • 
mmHg);
hypokalaemia (serum potassium <3.5 mmol/l);• 
renal insufficiency;• 
unresponsiveness to treatment.• 
In addition, further testing is recommended for excessive 
hyperlipidaemia (e.g. total cholesterol >8 mmol/l or total 
cholesterol/HDL cholesterol ratio >8).
Assessment of absolute CVd risk
For individuals without previous CVD and DM2, the 
ten-year risk of developing fatal CVD is assessed using the 
SCORE risk table, calibrated for Dutch CVD mortality data 
(table 1).2 The values for blood pressure and lipid levels in 
the table are applicable regardless of whether patients are 
treated with antihypertensive or lipid-lowering drugs.
Table 1. Risk of fatal cardiovascular disease (CVD) for patients without CVD and without diabetes mellitus type 2
Estimate of the level of the ten-year risk (%) of death from CVd in the Netherlands for non-smoking and smoking women and men aged 65, 60, 
55, 50 and 40 years with the aid of the sCorE risk function.
Smulders, et al. Cardiovascular risk management guideline.
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The presence of additional risk factors, including family 
history of premature CVD, (central) obesity, and physical 
inactivity, may lead to a higher risk than suggested in the 
SCORE risk table.
Nonpharmacological treatment
Recommendations for lifestyle modifications are 
given to all individuals with previous CVD, DM2 or an 
estimated ten-year risk of fatal CVD of ≥5%. Specific 
recommendations are outlined in figure 1, and are 
discussed in detail in the technical background document. 
Patients should be offered contact details of patient 
organisations that provide information and support for 
lifestyle interventions.
Pharmacological treatment
As illustrated in figure 1, three categories of individuals are 
distinguished for the purpose of tailoring pharmacological 
treatment. All recommendations are accompanied by 
footnotes in the technical background document.
Patients with CVD
Aspirin is recommended, unless there is a concomitant • 
condition requiring oral anticoagulation. In case of 
intolerance to aspirin, clopidogrel is a suitable alternative. 
Antihypertensive therapy is recommended if systolic • 
blood pressure is ≥140 mmHg or if a history of 
cerebrovascular disease (TIA or stroke) is present. The 
choice of drugs depends on comorbidity
Beta-receptor blockers are recommended for patients • 
with a history of coronary artery disease or heart failure 
due to coronary artery disease.
Angiotensin-converting-enzyme (ACE) inhibitors are • 
recommended for patients with a history of coronary 
revascularisation, myocardial infarction or heart failure 
due to coronary artery disease, even if systolic blood 
pressure is <140 mmHg.
Statin therapy is recommended if the plasma • 
LDL-cholesterol level is >2.5 mmol/l or, if LDL 
cholesterol is ≤2.5 mmol/l in very-high-risk patients 
characterised by the presence of multiple other risk 
factors (e.g. recurrent myocardial infarction, clustering 
of uncontrolled risk factors).
Patients with DM2
Antihypertensive therapy is recommended if systolic • 
blood pressure is ≥140 mmHg.
Statin therapy is recommended if the plasma • 
LDL-cholesterol level is >2.5 mmol/l, except in young 
patients with a low risk profile and good glycaemic control 
(i.e. HbA1c <7%). Conversely, a highly unfavourable risk 
profile (e.g. poor metabolic control, renal complications, 
clustering of risk factors) justifies statin treatment even 
if LDL cholesterol is ≤2.5 mmol/l.
Individuals free of CVD or DM2
Treatment recommendations for this group are based • 
on the estimated ten-year risk of fatal CVD. In general, 
smoking cessation is recommended prior to initiation 
of drug treatment.
Antihypertensive therapy is recommended if systolic • 
blood pressure is ≥140 mmHg and estimated ten-year 
risk of fatal CVD is ≥10%. Patients with a systolic blood 
pressure of ≥180 mmHg should receive antihypertensive 
treatment, regardless of their risk profile.
Statin therapy is recommended if the plasma • 
LDL-cholesterol level is >2.5 mmol/l and estimated 
ten-year risk of fatal CVD is ≥10%.
Individuals at intermediate CVD risk (5-10%) and • 
systolic blood pressure ≥140 mmHg or LDL cholesterol 
>2.5 mmol/l are amendable to antihypertensive or lipid 
lowering treatment, respectively, if at least one of the 
following is present:
- family history of premature CVD, i.e. <60 years in a 
parent or sibling;
- obesity, i.e. body mass index >30 kg/m2, or waist 
circum ference >88 cm (in women) or 102 cm (in 
men);
- target organ damage, such as (micro)albuminuria, 
renal insufficiency, or left ventricular hypertrophy.
Young individuals (<50 years) almost universally have a • 
ten-year risk of fatal CVD of <5%. Such individuals are 
nonetheless candidates for pharmacological treatment if 
there is clustering of multiple risk factors or a strongly 
positive family history of premature CVD.
Elderly individuals (>70-75 years) often have a high • 
(>10%) ten-year risk of fatal CVD based on their age 
alone. In principle, these individuals are candidates for 
preventive pharmacological treatment, but mass-scale 
polypharmacy and medicalisation should be avoided. 
Thus, treatment decisions must be individualised. As a 
rule, pharmacological primary CVD prevention requires 
that life expectancy is not limited due to comorbidity.
drug classes
Antiplatelet drugs are prescribed to all patients with • 
documented CVD. The standard recommended dose is 
80 mg of acetylsalicylic acid. Combination therapy with 
oral anticoagulants is not recommended. Aspirin is not 
recommended for primary prevention.
Antihypertensive drugs of different classes have, • 
on average, equally strong antihypertensive effects. 
Compelling indications for specific classes of 
antihypertensive drugs are listed in the full-text 
version of the guideline. If none are present, low-dose 
hydro chlorothiazide is recommended as initial drug. 
In the elderly, β-receptor blocker monotherapy is 
discouraged. Combination therapy is preferred over 
high-dose single-drug therapy. Blood pressure should be 
Smulders, et al. Cardiovascular risk management guideline.
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checked at two to four weekly intervals until the treatment 
goal is reached. The target level for systolic blood pressure 
is <140 mmHg. In patients with DM2, further lowering 
of systolic blood pressure is recommended.
Cholesterol-lowering drugs include statins as the only • 
standard recommended drugs. Simvastatin (40 mg) or 
pravastatin (40 mg) are drugs of first choice. The effect 
on LDL cholesterol should be assessed within three 
months of treatment. Target values are different for the 
following categories:
- patients with CVD or DM2 should reach a target 
LDL-cholesterol level of <2.5 mmol/l. If not, 
switching to atorvastatin or rosuvastatin could be 
considered. Addition of other lipid-lowering drugs 
lacks evidence base;
- individuals without CVD or DM2 who are prescribed 
a cholesterol-lowering drug for primary prevention 
should reach a target LDL-cholesterol level of <2.5 
mmol/l, or a decrease in LDL cholesterol after statin 
treatment of at least 1 mmol/l. 
follow-up
An individualised follow-up schedule is recommended 
for all patients. The aims of regular visits are to discuss 
compliance to lifestyle measures and drug treatment, and 
to evaluate treatment effects. A follow-up interval exceeding 
12 months is not recommended. Laboratory investigations 
depend on comorbidity and drug use. As most high-risk 
patients are at increased risk of developing DM2, fasting 
glucose measurement is recommended every three to five 
years. Interruption of pharmacological treatment is not 
recommended.
d i s C U s s i o N
In the full-text version of the guideline, many aspects of the 
guideline are discussed in more detail. However, a few areas 
of discussion deserve specific attention in this article.
Morbidity versus mortality risk
The guideline development group adopted the SCORE risk 
chart for estimating absolute cardiovascular risk, in contrast 
to previous Dutch guidelines, in which the Framingham 
risk score was used.3 The choice for SCORE was based 
on the higher number of included subjects in the source 
population and the fact that the risk model is based on a 
European population.2 The major drawback of SCORE 
is that only the risk of fatal CVD is estimated. Including 
nonfatal CVD risk, however, is paramount to quality-of-life 
aspects and to cost-effectiveness analyses of guidelines. 
Moreover, patients themselves are commonly interested in 
risk of morbidity rather than in risk of death alone. In annex 
2 of the guideline, a method for converting fatal to fatal plus 
nonfatal CVD risk is presented.
risk threshold for treatment
In the previous Dutch guideline for treatment of hypercho-
lesterolaemia, a 20% ten-year risk of fatal plus nonfatal 
CVD was recommended as a treatment threshold. This risk 
corresponds to the currently recommended risk threshold 
of 10% for fatal CVD. When the previous guidelines 
were being designed, arguments for determining the risk 
threshold included a cost-effectiveness analysis based on 
a cost estimate of Z 20,000 per quality-adjusted life year 
(QALY) for statin treatment. In the past decade, however, 
the cost of simvastatin, which is now available generically, 
has dropped from Z 700 to approximately Z 180 per year. 
Likewise, the cost of several antihypertensive drugs with 
established effectiveness and safety has decreased. The 
guideline development group decided that this decrease in 
costs should not lead to a lower risk threshold for preventive 
treatment. Lowering the risk threshold for fatal CVD from 
10 to 8%, for example, would have a major impact. Firstly, 
it would increase the ten-year number-needed-to-treat for 
simvastatin from 33 to 42 per fatal CVD event prevented. 
On a population scale, the impact would be substantial, 
as the number of currently untreated individuals in the 
Netherlands amendable to treatment with either a statin and/
or an antihypertensive drug would increase by almost one 
million (from 3,270,500 to 4,125,800). As a consequence, 
the impact this would have on the national health care 
budget would be substantial (1.1 billion euro after five years, 
assuming 100% prescription of the cheaper, generic drugs). 
Moreover, the guideline development group concluded that 
such large-scale medicalisation of the population would be 
undesirable.
risk assessment in dM
The SCORE risk chart does not calculate risk in patients 
with DM2. Although some studies have suggested that 
CVD risk in these patients equals risk in patients with 
a previous CVD diagnosis,4 the results of later studies 
were not conclusive.5,6 Obviously, there is substantial 
heterogeneity between patients with DM2 in terms of their 
CVD risk. The guideline development group decided to 
recommend low risk factor threshold levels for initiation 
of antihypertensive therapy (systolic blood pressure >140 
mmHg) and lipid-lowering therapy (LDL cholesterol >2.5 
mmol/l). Entering these thresholds in the United Kingdom 
Prospective Diabetes Study (UKPDS) risk engine (www.dtu.
ox.ac.uk/index.php?maindoc=/outcomesmodel) revealed 
that these values were usually related to absolute CVD risk 
levels above the 10% threshold used for preventive drug 
therapy in nondiabetics.7 Only if the remaining variables 
of the risk profile (e.g. age, glycaemic control, family 
history, ethnicity) are favourable do these blood pressure 
and LDL-cholesterol levels translate into risks lower than 
the treatment threshold. Therefore, the guideline included 
a statement on considering no statin treatment in young 
DM2 patients with a favourable risk profile.
Smulders, et al. Cardiovascular risk management guideline.
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risk estimation in young and elderly individuals
A major area of controversy is the use of absolute CVD risk 
estimates to guide preventive treatment in young and in 
elderly people. As is evident from figure 2, absolute ten-year 
CVD mortality risks rarely reach the 10% threshold in 
individuals below the age of 50 years. The guideline 
development group discussed the option of recommending 
extrapolation of absolute risk to the age of 60 years, 
as is suggested in the 2003 ESH/ESC hypertension 
guidelines.8 However, such extrapolation would result in an 
enormous increase in relatively young people who would be 
considered for drug therapy.9 Moreover, no strong evidence 
is available on the efficacy and safety of pharmacological 
CVD prevention beyond a period of more than ten years. 
Based on these arguments, the guideline development 
group decided to recommend drug treatment for primary 
CVD prevention in young individuals only if a risk factor is 
markedly increased or if clustering of multiple risk factors 
is present. It was also felt that no strict criteria should be 
defined for this purpose, and treatment decisions should 
always be individualised.
The reverse problem is encountered in elderly individuals, 
who almost universally reach the treatment threshold for 
preventive drug treatment as age progresses. This can be 
appreciated from table 1, although it requires extrapolation of 
the calculated risks, as the SCORE model does not calculate 
risks for individuals older than 65 years.2 The guideline 
development group acknowledged that antihypertensive 
and cholesterol-lowering drugs are also effective in the 
elderly. However, a standard recommendation to initiate 
these drugs in all elderly patients with a >10% ten-year 
risk of fatal CVD was considered undesirable, as it would 
lead to massive prescription, and thus medicalisation, 
in elderly people. Hence, as in younger people, a more 
liberal recommendation was made to consider preventive 
treatment in elderly, and to decide on drug treatment based 
on risk profile, general health and life-expectancy and 
patient preferences.
implementation of the guideline
The guideline was made publicly accessible via the internet 
(www.cbo.nl/product/richtlijnen/folder20021023121843/
rl_overzicht). The printed version of the guideline was 
freely distributed to all general practitioners, as well as to all 
physicians registered in Internal Medicine, Cardiology, and 
Neurology. In addition, a patient brochure and risk calculator 
were produced and distributed. Based on the guidelines, an 
internet-based ‘decision aid’ was made publicly available to 
help patients to make informed treatment decisions. 
Following endorsement of the guideline, a nationwide 
platform was established consisting of representatives from 
patient organisations and health professional associations. 
The mission of this platform is to facilitate and optimise 
implementation of the guideline.
Updating of the guideline
The Dutch Institute for Health Care Improvement 
CBO aims to update the literature and modify the 
recommendations, if needed, at least every two years.
N o T E
Members of the guideline development group Dutch 
guideline cardiovascular risk management: W.A.B. 
Stalman (chair), T. Scheltens, J.S. Burgers, C.W.P.M. 
Hukkelhoven, S.M. Smorenburg, J.D. Banga, D.W.J. Dippel, 
S.J. van Dis, D.E. Grobbee, A.W. Hoes, B.A. van Hout, J.W. 
Jukema, P.J.E.H.M. Kitslaar, D. Kromhout, R.J. Peters, M.L. 
Simoons, Y.M. Smulders, C.D.A. Stehouwer, S. Thomas, 
E.P. Walma, Tj. Wiersma.
Participating associations: Dutch Institute for Health 
Care Improvement CBO, Dutch Association for Internal 
Medicine NIV, Netherlands Heart Foundation, Netherlands 
Association for Cardiology NVVC, Netherlands Association 
for Surgery NVVH, Netherlands Association for Neurology 
NVVN, Dutch College of General Practitioners NHG, 
Dutch Epidemiology Association.
r E f E r E N C E s
DeBacker G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines 1. 
on cardiovascular disease prevention in clinical practice: third joint task 
force of European and other societies on cardiovascular disease prevention 
in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-10.
Conroy RM, Pyorälä K, Fitzgerald AP, et al. Estimation of ten-year risk of 2. 
fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 
2003;24:987-1003.
Anderson KM, Wilson PWF, Odell PM, Kannal WB. An updated 3. 
cardiovascular risk profile. Circulation 1991;83:356-62.
Haffner SM, Lehto S, Rönnema T, Pyörälä K, Laasko M. Mortality 4. 
from coronary heart disease in subjects with type 2 diabetes and in 
non-diabetic subjects with and without prior myocardial infarction. 
N Engl J Med 1998;339:229-34.
Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk 5. 
between patients with type 2 diabetes and those who had had a myocardial 
infarction: cross sectional and cohort studies. BMJ 2002;324:939.
Lee CD, Folsom AR, Pankow JS, Brancati FL, For the Atherosclerosis 6. 
Risk in Communities (ARIC) Study Investigators. Cardiovascular events 
in diabetic and nondiabetic adults with or without history of myocardial 
infarction. Circulation 2004;109:855-60.
Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk 7. 
engine: a model for the risk of coronary heart disease in type II diabetes. 
Clin Sci 2001;101:671-9.
Guidelines Committee. 2003 European Society of Hypertension – European 8. 
Society of Cardiology guidelines for the management of arterial hypertension. 
J Hypertens 2003;21:1011-53.
Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. 9. 
Estimating the high risk group for cardiovascular disease in the Norwegian 
HUNT 2 population according to the 2003 European guidelines: modelling 
study. BMJ 2005;331:551.
Smulders, et al. Cardiovascular risk management guideline.
